- Home
- TCGX vs UNCY Comparison
TCGX vs UNCY Comparison
Compare TCGX & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TCGX | UNCY |
|---|---|---|
| Founded | 2026 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 113.4M | 100.6M |
| IPO Year | 2026 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TCGX | UNCY |
|---|---|---|
| Price | $10.04 | $3.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $28.40 |
| AVG Volume (30 Days) | 238.9K | ★ 1.1M |
| Earning Date | N/A | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $675,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10,044.55 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.90 | $3.33 |
| 52 Week High | $18.91 | $8.74 |
Technical Indicators
Market Signals| Indicator | TCGX | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 29.87 | 40.82 |
| Support Level | $9.90 | $3.35 |
| Resistance Level | $10.19 | $4.18 |
| Average True Range (ATR) | 0.26 | 0.25 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 4.49 | 38.84 |
Price Performance
Historical ComparisonAbout TCGX TCGX Acquisition Corp. Class A Ordinary Shares
TCGX Acquisition Corp is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.